ProCE Banner Activity

I-SPY 2.2: Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in High-Risk Stage II-III HER2-Negative Breast Cancer

Conference Coverage

In the I-SPY 2.2 trial, neoadjuvant datopotamab deruxtecan plus durvalumab was deemed effective in the immune+ response–predictive subtype in patients with stage II-III breast cancer considered high risk by 70-gene assay, allowing early surgery without chemotherapy. 

Released: June 07, 2024

Expiration: June 06, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Novartis Pharmaceuticals Corporation.


Daiichi Sankyo, Inc.

Novartis Pharmaceuticals Corporation